Literature DB >> 17653653

Frequent activation of mitogen-activated protein kinase relative to Akt in extrahepatic biliary tract cancer.

Hiroshige Hori1, Tetsuo Ajiki, Yoshiyasu Mita, Hideki Horiuchi, Kenro Hirata, Taku Matsumoto, Haruki Morimoto, Tsunenori Fujita, Yonson Ku, Yoshikazu Kuroda.   

Abstract

BACKGROUND: Lack of effective adjuvant therapy against advanced extrahepatic biliary tract carcinoma (BTC) requires that new therapeutic methods, such as molecular targeted therapy, be developed. The mitogen-activated protein kinase (MAPK) and Akt signaling pathways, which activate cell proliferation and suppress apoptosis, respectively, may function as important targets for such therapies. The aim of this study was to examine the expression patterns of phosphorylated MAPK (p-MAPK) and phosphorylated Akt (p-Akt) proteins in BTC cell lines and clinical specimens.
METHODS: Expression of p-MAPK and p-Akt proteins in four human BTC cell lines and in frozen sections of 20 advanced extrahepatic BTC specimens was analyzed by Western blotting. Thirty formalin-fixed BTC specimens were immunohistochemically stained for p-MAPK and p-Akt using labeled streptavidin-biotin conjugates.
RESULTS: Expression of p-MAPK was observed in three of four (75%) BTC cell lines, whereas no expression of p-Akt was observed. Twenty-three of 30 formalin-fixed specimens stained positive for p-MAPK (77%), whereas only 47% stained positively for p-Akt. Expression of p-MAPK relative to that of p-Akt was also seen more frequently in the frozen specimens.
CONCLUSIONS: The results of this study suggest that MAPK is activated more frequently than Akt in extrahepatic biliary tract carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653653     DOI: 10.1007/s00535-007-2055-7

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  40 in total

1.  K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct.

Authors:  K Hanada; M Itoh; K Fujii; A Tsuchida; H Ooishi; G Kajiyama
Journal:  Cancer       Date:  1996-02-01       Impact factor: 6.860

Review 2.  PI3K: downstream AKTion blocks apoptosis.

Authors:  T F Franke; D R Kaplan; L C Cantley
Journal:  Cell       Date:  1997-02-21       Impact factor: 41.582

3.  Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer.

Authors:  T Todoroki; T Kawamoto; M Otsuka; N Koike; S Yoshida; Y Takada; S Adachi; H Kashiwagi; K Fukao; K Ohara
Journal:  Hepatogastroenterology       Date:  1999 May-Jun

4.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

Authors:  M Sun; G Wang; J E Paciga; R I Feldman; Z Q Yuan; X L Ma; S A Shelley; R Jove; P N Tsichlis; S V Nicosia; J Q Cheng
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

5.  Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience.

Authors:  Y Nimura; J Kamiya; S Kondo; M Nagino; K Uesaka; K Oda; T Sano; H Yamamoto; N Hayakawa
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

6.  Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines.

Authors:  K Nakatani; D A Thompson; A Barthel; H Sakaue; W Liu; R J Weigel; R A Roth
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

7.  Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth.

Authors:  Yoko Yamagiwa; Carla Marienfeld; Laura Tadlock; Tushar Patel
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

8.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors:  A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

9.  Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

Authors:  William R Jarnagin; Leyo Ruo; Sarah A Little; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Raquel Wagman; Leslie H Blumgart; Yuman Fong
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

10.  Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein.

Authors:  S J Leevers; C J Marshall
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  5 in total

1.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

2.  A potent therapeutics for gallbladder cancer by combinatorial inhibition of the MAPK and mTOR signaling networks.

Authors:  Dai Mohri; Hideaki Ijichi; Koji Miyabayashi; Ryota Takahashi; Yotaro Kudo; Takashi Sasaki; Yoshinari Asaoka; Yasuo Tanaka; Tsuneo Ikenoue; Keisuke Tateishi; Minoru Tada; Hiroyuki Isayama; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2015-11-27       Impact factor: 7.527

3.  Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.

Authors:  Richard D Kim; Shannon McDonough; Anthony B El-Khoueiry; Tanios S Bekaii-Saab; Stacey M Stein; Vaibhav Sahai; George P Keogh; Edward J Kim; Ari D Baron; Abby B Siegel; Afsaneh Barzi; Katherine A Guthrie; Milind Javle; Howard Hochster
Journal:  Eur J Cancer       Date:  2020-03-29       Impact factor: 9.162

4.  Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations.

Authors:  Qinglong Li; Zhulin Yang
Journal:  J Exp Clin Cancer Res       Date:  2009-05-18

5.  Molecular biomarkers in extrahepatic bile duct cancer patients undergoing chemoradiotherapy for gross residual disease after surgery.

Authors:  Hyeon Kang Koh; Hae Jin Park; Kyubo Kim; Eui Kyu Chie; Hye Sook Min; Sung W Ha
Journal:  Radiat Oncol J       Date:  2012-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.